150 related articles for article (PubMed ID: 37116546)
1. The match between adhesive mixture powder formulations for inhalation and the inhaler device.
Thalberg K; Ahmadi R; Stuckel J; Elfman P; Svensson M
Eur J Pharm Sci; 2023 Jul; 186():106457. PubMed ID: 37116546
[TBL] [Abstract][Full Text] [Related]
2. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246
[TBL] [Abstract][Full Text] [Related]
3. The effect of budesonide particle mass on drug particle detachment from carrier crystals in adhesive mixtures during inhalation.
Dickhoff BH; Ellison MJ; de Boer AH; Frijlink HW
Eur J Pharm Biopharm; 2002 Sep; 54(2):245-8. PubMed ID: 12191698
[TBL] [Abstract][Full Text] [Related]
4. The effect of mixing on the dispersibility of adhesive mixtures for inhalation. Comparison of high shear and Turbula mixers.
Thalberg K; Ivarsson L; Svensson M; Elfman P; Ohlsson A; Stuckel J; Lyberg AM
Eur J Pharm Sci; 2024 Feb; 193():106679. PubMed ID: 38128841
[TBL] [Abstract][Full Text] [Related]
5. Effects of the mouthpiece and chamber of Turbuhaler® on the aerosolization of API-only powder formulations.
Zhu Q; Gou D; Chan HK; Kourmatzis A; Yang R
Int J Pharm; 2023 Apr; 637():122871. PubMed ID: 36948474
[TBL] [Abstract][Full Text] [Related]
6. Development of drug alone and carrier-based GLP-1 dry powder inhaler formulations.
Babenko M; Alany RG; Calabrese G; Kaialy W; ElShaer A
Int J Pharm; 2022 Apr; 617():121601. PubMed ID: 35181460
[TBL] [Abstract][Full Text] [Related]
7. Comparative in vitro performance evaluation of the Novopulmon 200 Novolizer and Budesonid-ratiopharm Jethaler: two novel budesonide dry powder inhalers.
de Boer AH; Gjaltema D; Hagedoorn P; Frijlink HW
Pharmazie; 2004 Sep; 59(9):692-9. PubMed ID: 15497751
[TBL] [Abstract][Full Text] [Related]
8. Difference in resistance to humidity between commonly used dry powder inhalers: an in vitro study.
Janson C; Lööf T; Telg G; Stratelis G; Nilsson F
NPJ Prim Care Respir Med; 2016 Nov; 26():16053. PubMed ID: 27853177
[TBL] [Abstract][Full Text] [Related]
9. Investigations on the Mechanism of Magnesium Stearate to Modify Aerosol Performance in Dry Powder Inhaled Formulations.
Jetzer MW; Schneider M; Morrical BD; Imanidis G
J Pharm Sci; 2018 Apr; 107(4):984-998. PubMed ID: 29247741
[TBL] [Abstract][Full Text] [Related]
10. Potential and constraints for the application of CFD combined with Lagrangian particle tracking to dry powder inhalers.
Sommerfeld M; Cui Y; Schmalfuß S
Eur J Pharm Sci; 2019 Feb; 128():299-324. PubMed ID: 30553814
[TBL] [Abstract][Full Text] [Related]
11. Role of dispersion enhancer selection in the development of novel tratinterol hydrochloride dry powder inhalation formulations.
Liu T; Tong S; Liao Q; Pan L; Cheng M; Rantanen J; Cun D; Yang M
Int J Pharm; 2023 Mar; 635():122702. PubMed ID: 36773729
[TBL] [Abstract][Full Text] [Related]
12. Formulating powder-device combinations for salmeterol xinafoate dry powder inhalers.
Hassoun M; Ho S; Muddle J; Buttini F; Parry M; Hammond M; Forbes B
Int J Pharm; 2015 Jul; 490(1-2):360-7. PubMed ID: 25987210
[TBL] [Abstract][Full Text] [Related]
13. Effect of Flow Rate on In Vitro Aerodynamic Performance of NEXThaler(®) in Comparison with Diskus(®) and Turbohaler(®) Dry Powder Inhalers.
Buttini F; Brambilla G; Copelli D; Sisti V; Balducci AG; Bettini R; Pasquali I
J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):167-78. PubMed ID: 26355743
[TBL] [Abstract][Full Text] [Related]
14. Segregation in inhalable powders: Quantification of the effect of vibration on adhesive mixtures.
Sarangi S; Simonsson A; Frenning G
Eur J Pharm Biopharm; 2023 Jun; 187():107-119. PubMed ID: 37100091
[TBL] [Abstract][Full Text] [Related]
15. Impact of dispersion media and carrier type on spray-dried proliposome powder formulations loaded with beclomethasone dipropionate for their pulmonary drug delivery via a next generation impactor.
Khan I; Al-Hasani A; Khan MH; Khan AN; -Alam FE; Sadozai SK; Elhissi A; Khan J; Yousaf S
PLoS One; 2023; 18(3):e0281860. PubMed ID: 36913325
[TBL] [Abstract][Full Text] [Related]
16. From laminar to turbulent flow in a dry powder inhaler: The effect of simple design modifications.
Singh G; Tang P; Cheng S; Chan HK; Kourmatzis A
Int J Pharm; 2022 Mar; 616():121556. PubMed ID: 35131350
[TBL] [Abstract][Full Text] [Related]
17. Defining the critical material attributes of lactose monohydrate in carrier based dry powder inhaler formulations using artificial neural networks.
Kinnunen H; Hebbink G; Peters H; Shur J; Price R
AAPS PharmSciTech; 2014 Aug; 15(4):1009-20. PubMed ID: 24831088
[TBL] [Abstract][Full Text] [Related]
18. Novolizer: how does it fit into inhalation therapy?
Magnussen H
Curr Med Res Opin; 2005; 21 Suppl 4():S39-46; discussion S47. PubMed ID: 16138944
[TBL] [Abstract][Full Text] [Related]
19. A quantitative approach to predicting lung deposition profiles of pharmaceutical powder aerosols.
Yaqoubi S; Chan HK; Nokhodchi A; Dastmalchi S; Alizadeh AA; Barzegar-Jalali M; Adibkia K; Hamishehkar H
Int J Pharm; 2021 Jun; 602():120568. PubMed ID: 33812969
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of granulated lactose as a carrier for DPI formulations 1: effect of granule size.
Du P; Du J; Smyth HD
AAPS PharmSciTech; 2014 Dec; 15(6):1417-28. PubMed ID: 24962007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
